Results 11 to 20 of about 108,835 (233)

Burden of visceral leishmaniasis in villages of eastern gedaref state, Sudan: an exhaustive cross-sectional survey. [PDF]

, 2012
Since December 2009, Médecins Sans Frontières has diagnosed and treated patients with visceral leishmaniasis (VL) in Tabarak Allah Hospital, eastern Gedaref State, one of the main endemic foci of VL in Sudan.
A Ismail, A Stauch, AB Joshi, AM Musa, B Bucheton, CP Thakur, Dagemlidet Worku, DE Elnaiem, DE Elnaiem, EA Khalil, EE Zijlstra, EE Zijlstra, EE Zijlstra, EE Zijlstra, F Chappuis, Fabienne Nackers, François Chappuis, GK Adam, H Veeken, Hechmi Louzir, Himida Ali Gorashi, Jean-Claude Djoumessi, Jean-François Etard, JH Kolaczinski, K Ritmeijer, K Ritmeijer, K Ritmeijer, Khalid A. Ahmed, Koert Ritmeijer, Marleen Boelaert, Niven Salih, OF Osman, Omer Hammam, Rahma Eltigani, SE Meredith, Y Mueller, Yolanda Kathrin Mueller, ZM Luz   +37 more
core   +24 more sources

Exploring Host-Specificity: Untangling the Relationship between Leishmania (Viannia) Species and Its Endosymbiont Leishmania RNA Virus 1

Microorganisms, 2023
A relevant aspect in the epidemiology of Tegumentary Leishmaniasis (TL) are the Leishmania parasites carrying a viral endosymbiont, Leishmania RNA Virus 1 (LRV1), a dsRNA virus.
Mayara Cristhine de Oliveira Santana, Khaled Chourabi, Lilian Motta Cantanhêde, Elisa Cupolillo   +3 more
doaj   +1 more source

Unusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid‐induced immunosuppression

Clinical Case Reports, 2021
Clinicians should always consider rare, atypical, and opportunistic infections in patients undergoing long‐term systemic corticosteroid therapy. Diagnosis needs further evaluations and special consideration.
Maryam Mahdavi, Reihaneh Aryan, Yalda Nahidi, Mehrdad Teimoorian, Vahid Mashayekhi   +4 more
doaj   +1 more source

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. [PDF]

, 2011
Due to unacceptably high mortality with pentavalent antimonials, Médecins Sans Frontières in 2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients in Ethiopia who were severely ill or positive for human ...
Aderie, Endashaw Mengistu, Chane, Solomon, Collin, Simon M, Davidson, Robert N, Piening, Turid, Ritmeijer, Koert, ter Horst, Rachel   +6 more
core   +2 more sources

Leishmaniasis [PDF]

Postgraduate Medical Journal, 2006
Abstract Epidemiology, disease patterns, immunology, diagnosis, treatment and control measures of leishmaniasis are described. Various issues relating to leishmaniasis are highlighted: the relative lack of importance given to this disease is compared with other infections, climate change and its possible effect on extension of endemicity
Tonio V, Piscopo, Charles, Mallia Azzopardi   +1 more
openaire   +4 more sources

Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice

Parasites & Vectors, 2020
Background Leishmaniasis is a serious health problem in some parts of the world. In spite of the many known leishmaniasis control measures, the disease has continued to increase in endemic areas, and no effective vaccine has been discovered.
Samira Salari, Iraj Sharifi, Ali Reza Keyhani, Pooya Ghasemi Nejad Almani   +3 more
doaj   +1 more source

Leishmaniasis: new approaches to disease control. [PDF]

, 2003
The leishmaniases afflict the world's poorest populations. Among the two million new cases each year in the 88 countries where the disease is endemic (fig 1), it is estimated that 80% earn less than $2 a day.
Croft, Simon L, Davies, Clive R, Kaye, Paul, Sundar, Shyam   +3 more
core   +2 more sources

Insights from mathematical modelling and quantitative analysis on the proposed WHO 2030 targets for visceral leishmaniasis on the Indian subcontinent [version 1; peer review: 2 approved]

Gates Open Research, 2019
Visceral leishmaniasis (VL) is a neglected tropical disease (NTD) caused by Leishmania protozoa that are transmitted by female sand flies. On the Indian subcontinent (ISC), VL is targeted by the World Health Organization (WHO) for elimination as a public
NTD Modelling Consortium Visceral Leishmaniasis Group
doaj   +1 more source

Leishmaniasis [PDF]

hautnah dermatologie, 2015
ZusammenfassungInfektionen mit Leishmanien gehören zu den Top 3 der häufigsten Reisedermatosen. Je nach Reiseland und Immunstatus des Patienten unterscheiden sich die Krankheitsbilder. Die Infektion bildet sich in 90 % der Fälle als kutane Leishmaniasis aus, kann sich aber auch an den inneren Organen manifestieren (viszerale Leishmaniasis).
openaire   +4 more sources

Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients

Journal of Tropical Medicine, 2013
Visceral leishmaniasis (VL) is a parasitic disease characterized by immune suppression. Successful treatment is usually followed by immune reconstitution and a dermatosis called post-Kala-azar dermal leishmaniasis (PKDL).
Eltahir Awad Gasim Khalil, Selma Abdelmoneim Khidir, Ahmed Mudawi Musa, Brema Younis Musa, Mona Elfaki Eltahir Elfaki, Abdelgadir Mohamed Yousif Elkadaru, Edward Zijlstra, Ahmed Mohamed El-Hassan   +7 more
doaj   +1 more source